Clinical applications of the interleukins: present and future.
Clinical use of biologic agents, especially in the fields of hematology and oncology, is becoming increasingly common. Many agents, interferon-alpha, interferon-gamma, granulocyte and granulocyte-monocyte colony stimulating factors, erythropoietin, and interleukin-2 have already been approved for clinical use. Others are currently in clinical trials or will soon be available for administration to humans. This review summarizes the properties of interleukins 1 through 12, their derivation, activities, and approved or potential clinical uses.
Holcombe
R F
RF
LSUMC-Shreveport.
D000328:Adult; D002292:Carcinoma, Renal Cell / Q000628:therapy; D002986:Clinical Trials as Topic; D005544:Forecasting; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use; D007378:Interleukins / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy
D007376:Interleukin-2; D007378:Interleukins